These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8895098)

  • 1. Structural requirements for cathepsin B and cathepsin H inhibition by kininogens.
    Bano B; Kunapuli SP; Bradford HN; Colman RW
    J Protein Chem; 1996 Aug; 15(6):519-25. PubMed ID: 8895098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterisation of chicken L- and H-kininogens and their interaction with chicken cysteine proteinases and papain.
    Kos J; Dolinar M; Turk V
    Agents Actions Suppl; 1992; 38 ( Pt 1)():331-9. PubMed ID: 1466284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new function of kininogens as thiol-proteinase inhibitors: inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens.
    Sueyoshi T; Enjyoji K; Shimada T; Kato H; Iwanaga S; Bando Y; Kominami E; Katunuma N
    FEBS Lett; 1985 Mar; 182(1):193-5. PubMed ID: 3972123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrids of chicken cystatin with human kininogen domain 2 sequences exhibit novel inhibition of calpain, improved inhibition of actinidin and impaired inhibition of papain, cathepsin L and cathepsin B.
    Auerswald EA; Nägler DK; Gross S; Assfalg-Machleidt I; Stubbs MT; Eckerskorn C; Machleidt W; Fritz H
    Eur J Biochem; 1996 Feb; 235(3):534-42. PubMed ID: 8654398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the kininogens as cysteine proteinase inhibitors in local and systemic inflammation.
    Assfalg-Machleidt I; Billing A; Fröhlich D; Nast-Kolb D; Joka T; Jochum M; Machleidt W
    Agents Actions Suppl; 1992; 38 ( Pt 1)():312-21. PubMed ID: 1466282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.
    Kunapuli SP; Bradford HN; Jameson BA; DeLa Cadena RA; Rick L; Wassell RP; Colman RW
    J Biol Chem; 1996 May; 271(19):11228-35. PubMed ID: 8626672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The occluding loop of cathepsin B prevents its effective inhibition by human kininogens.
    Naudin C; Lecaille F; Chowdhury S; Krupa JC; Purisima E; Mort JS; Lalmanach G
    J Mol Biol; 2010 Jul; 400(5):1022-35. PubMed ID: 20538006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design.
    Ménard R; Therrien C; Lachance P; Sulea T; Qo H; Alvarez-Hernandez AD; Roush WR
    Biol Chem; 2001 May; 382(5):839-45. PubMed ID: 11517939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human plasma kininogens are identical with alpha-cysteine proteinase inhibitors. Evidence from immunological, enzymological and sequence data.
    Müller-Esterl W; Fritz H; Machleidt W; Ritonja A; Brzin J; Kotnik M; Turk V; Kellermann J; Lottspeich F
    FEBS Lett; 1985 Mar; 182(2):310-4. PubMed ID: 2579850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsins X and B can be differentiated through their respective mono- and dipeptidyl carboxypeptidase activities.
    Therrien C; Lachance P; Sulea T; Purisima EO; Qi H; Ziomek E; Alvarez-Hernandez A; Roush WR; Ménard R
    Biochemistry; 2001 Mar; 40(9):2702-11. PubMed ID: 11258881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The slow-binding inhibition of cathepsin K by its propeptide.
    Billington CJ; Mason P; Magny MC; Mort JS
    Biochem Biophys Res Commun; 2000 Oct; 276(3):924-9. PubMed ID: 11027570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SEP domain of p47 acts as a reversible competitive inhibitor of cathepsin L.
    Soukenik M; Diehl A; Leidert M; Sievert V; Büssow K; Leitner D; Labudde D; Ball LJ; Lechner A; Nägler DK; Oschkinat H
    FEBS Lett; 2004 Oct; 576(3):358-62. PubMed ID: 15498563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo.
    Towatari T; Nikawa T; Murata M; Yokoo C; Tamai M; Hanada K; Katunuma N
    FEBS Lett; 1991 Mar; 280(2):311-5. PubMed ID: 2013329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new purification procedure of human kidney cathepsin H, its properties and kinetic data.
    Popović T; Brzin J; Kos J; Lenarcic B; Machleidt W; Ritonja A; Hanada K; Turk V
    Biol Chem Hoppe Seyler; 1988 May; 369 Suppl():175-83. PubMed ID: 3202963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens.
    Turk V; Brzin J; Kotnik M; Lenarcic B; Popović T; Ritonja A; Trstenjak M; Begić-Odobasić L; Machleidt W
    Biomed Biochim Acta; 1986; 45(11-12):1375-84. PubMed ID: 3495261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary structure of bovine cathepsin S. Comparison to cathepsins L, H, B and papain.
    Wiederanders B; Broemme D; Kirschke H; Kalkkinen N; Rinne A; Paquette T; Toothman P
    FEBS Lett; 1991 Jul; 286(1-2):189-92. PubMed ID: 1864368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous isolation of human kidney cathepsins B, H, L and C and their characterisation.
    Popovic T; Puizdar V; Ritonja A; Brzin J
    J Chromatogr B Biomed Appl; 1996 Jun; 681(2):251-62. PubMed ID: 8811434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of N-terminal region residues of cystatin A (stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B, and cathepsin L.
    Estrada S; Pavlova A; Björk I
    Biochemistry; 1999 Jun; 38(22):7339-45. PubMed ID: 10353845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides.
    Guay J; Falgueyret JP; Ducret A; Percival MD; Mancini JA
    Eur J Biochem; 2000 Oct; 267(20):6311-8. PubMed ID: 11012686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Ha-ras gene products are potent inhibitors of cathepsins B and L.
    Hiwasa T; Yokoyama S; Ha JM; Noguchi S; Sakiyama S
    FEBS Lett; 1987 Jan; 211(1):23-6. PubMed ID: 3542564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.